PTC Advances Cystic Fibrosis Candidate On Encouraging Data
Company is pursuing PTC124 in nonsense-mutation-mediated CF, a patient population of about 3,000 in the U.S.
Company is pursuing PTC124 in nonsense-mutation-mediated CF, a patient population of about 3,000 in the U.S.